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Modern strategies in drug development employ in silico techniques in the design
of compounds as well as estimations of pharmacokinetics, pharmacodynamics and
toxicity parameters. The quality of the results depends on software algorithm, data
library and input data. Compared to simulations of absorption, distribution, metabolism,
excretion, and toxicity of oral drug compounds, relatively few studies report predictions
of pharmacokinetics and pharmacodynamics of inhaled substances. For calculation of
the drug concentration at the absorption site, the pulmonary epithelium, physiological
parameters such as lung surface and distribution volume (lung lining fluid) have to
be known. These parameters can only be determined by invasive techniques and by
postmortem studies. Very different values have been reported in the literature. This review
addresses the state of software programs for simulation of orally inhaled substances
and focuses on problems in the determination of particle deposition, lung surface and
of lung lining fluid. The different surface areas for deposition and for drug absorption are
difficult to include directly into the simulations. As drug levels are influenced by multiple
parameters the role of single parameters in the simulations cannot be identified easily.
Keywords: in silico modeling, inhalation, lung surface area, deposition, lung lining fluid
INTRODUCTION
Drug delivery by non-invasive alternative routes, such as dermal, oral and pulmonary delivery
has much improved in the last years. Compared to the invasive routes, intravenous injection,
intramuscular, subcutaneous application, etc. alternative routes have a greater patient compliance
because they do not need attendance at the doctor’s office and they are less painful than parenteral
applications. Drug delivery by non-invasive routes has been improved due to the development
of formulations with specific profiles (immediate release and modified release), co-administration
with inhibitors, absorption enhancers and new devices for application (inhalers, needles).
Furthermore, in silico methods have been developed in the last decades, which allow designing
specific molecules, and prediction of absorption, tissue distribution, metabolism, excretion and
toxicity to a reasonably good degree. Simulation programs, such as GastroPlusTM, SimCYP R©,
PK-SIM R©, Matlab R©, Stella R© and ChloePK R© can simulate physiologically based pharmacokinetics
(PBPK) of drugs applied mainly by the oral route, based on a mixture of in silico, in vitro and in
vivo data as input parameters (van de Waterbeemd and Gifford, 2003; Kostewicz et al., 2014). For
example, in vitro measured and/or in silico predicted physico-chemical parameters like logP and
solubility for the compound and in vivo pharmacokinetic parameters for the exposed individual
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are combined in a single modeling. In general, the extent of
inter-individual differences can be included in the simulation
by modification of physiological parameters such as: tissue
volumes and composition; physiological flow rates, tissue:blood
partition coefficients, enzymes and transporters expression
levels and filtration rates (Lipscomb et al., 2012; Reddy
et al., 2013). The mechanistic PBPK models provide a
physiological framework, which facilitates the incorporation of
all the relevant Absorption, Distribution, Metabolization, and
Elimination (ADME) processes, when the respective data are
available (Jones et al., 2009; Kostewicz et al., 2014).
Compared to oral application, prediction of plasma profiles
of inhaled drugs is rarely reported. However, several software
have been developed to calculate these values, including
computational fluid dynamics (CFD), GastroPlusTM, and
other compartmental pharmacokinetics/pharmacodynamics
(PK/PD) models to calculate these values (Patterson, 2015).
These models use airway thickness, surface area, transporter
activities, lysosomal degradation, and mitochondrial activities
as physiological parameters (Yu and Rosania, 2010). Several
biological parameters like the permeation of the epithelial
barrier can be calculated by software programs or determined
experimentally using either cell monolayer or tissue explants
(Fröhlich et al., 2012) and physiologically relevant exposure
conditions for pulmonary exposure can be developed from
existing set-ups (Fröhlich and Salar-Behzadi, 2014). In addition
to absorption area and fluid available for dissolution, distribution
and deposition of inhaled particles in the respiratory system
determines drug concentration at the pulmonary barrier.
Measurement of particle deposition in vivo is technically
complicated but software solutions are available to help in the
prediction of lung deposition. There are, however, no alternatives
to in vivo determinations of lung surface area and lung lining
fluid. This review will discuss the experimental techniques and
required data for the determination of lung surface area and lung
lining fluid as well as the modeling of particle deposition in the
lung. The impact of critical parameters on the estimations and
developed models will be also reviewed.
PARTICLE DEPOSITION IN THE LUNG
Several in vivo methods can determine particle deposition in
the lung based on the use of radioactively labeled aerosols.
The methodology is technically demanding, needs specific
tracers and is expensive. Furthermore, available techniques
such as single-photon emission computed tomography (SPECT),
positron emission tomography (PET), and γ-scintigraphy
provide different information. Data are mostly indicated as total
lung deposition, comprising deposition in the conducting and the
peripheral airways. The penetration index (PI; the ratio between
deposition in conducting and peripheral airways) provides
information to which extent the particles reach the alveoli, where
absorption mainly takes place. The available technologies have
different advantages and limitations; planar (two dimensional)
γ-scintigraphy is the least expensive technique, but does not
allow good separation between peripheral and medium/small
airways because these regions overlap in planar view (Hickey and
Swift, 2011). However, 3D information in γ-scintigraphy can be
obtained by taking anterior-posterior and lateral images (Phipps
et al., 1989). SPECT and PET are 3-dimensional techniques
and, therefore, provide better spatial information. The main
disadvantage of SPECT is the long imaging time (∼20 min
compared to 5 min with the γ-camera). During this time,
the particles in the upper airways can be cleared (Ruzer and
Harley, 2013). PET is particularly complex because cyclotron
for radioactive labeling of imaging agent with short half-life,
which should be used immediately after synthesis, is not available
at many hospitals. Differences in the determination methods
were analyzed in more detail by Biddiscombe et al. (2011). The
authors pointed out that different approaches result in different
deposition values and that methodologies, therefore, should be
standardized to facilitate data comparison between laboratories
and normalize data. It is for instance known that 3D imaging
identified greater differences in the PI between small (Mass
Median Aerodynamic Diameter (MMAD) of 2.6 µm) and large
(MMAD= 5.5 µm) particles, than 2D imaging.
Due to the fact that in vivo lung deposition measurements
are cost-intense, need time for evaluation and are not well
standardized, there is an arising interest for computational
models. The majority of such models can be divided into
empirical, mechanistic, and stochastic ones. Empirical models
are based on mathematical equations fitted to experimental
data. Using these models, pathways in the respiratory tract
are considered as identical with linear dimensions, and the
deposition is calculated in the whole lung. The particle deposition
in individual airways is calculated by using analytical deposition
equations for pre-specified flow conditions and the average
behavior of particles are calculated. Realistic description of
lung structure and physiology is used for the development of
mechanistic models, taking into account different breathing
scenarios and parameters. Moreover, fluid and particle dynamics
are correlated with respiration by simplified expressions for
calculation of resulting particle motion (Rosati et al., 2004).
These models are based on either idealized descriptions of lung
morphology and physiology by CFD, or calculation of inhaled
aerosol flow by considering the fate of a population of particles
or an individual particle (Eulerian and Lagrangian models,
respectively). In the models branching angles are included,
which are difficult to determine in small airways and change
from resting to deep inhalation. The angle of the tracheal
bifurcation decreases from a value of 70◦ up to 10◦ upon deep
inspiration (Breatnach et al., 1984; Holbert and Strollo, 1995).
Both Eulerian and Lagrangian models can be used for modeling
the whole lung or a local scale approach (Martonen et al., 1997;
Zhang and Kleinstreuer, 2002; Hofmann, 2011). Examples for
the Eulerian approach for the simulation of deposition at the
whole lung level are the deterministic generation-based models
(Yeh and Schum, 1980; Hofmann et al., 1989; Martonen, 1993),
and the one-dimensional trumpet model (Egan and Nixon,
1985; Mitsakou et al., 2005). In all these cases the intersubject
variability of physiological and morphological data is a limiting
factor. The description of lung pathway can be also used for
deterministic or stochastic models (Bradley et al., 1981; Hofmann
and Koblinger, 1990, 1992; Koblinger and Hofmann, 1990;
Asgharian et al., 2001; Longest et al., 2004; Mitsakou et al.,
2005; Zhang et al., 2008, 2009; Hofmann, 2011; Longest and
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Holbrook, 2012).Stochastic modeling is a great step toward
the improvement of the problem of intersubject variability,
by using random variation of the geometry of the airways
for incorporating the biological variability. Different deposition
models and the required physiological and morphological data
with the evaluation of their advantages and drawbacks have been
extensively reviewed elsewhere (Rosati et al., 2004; Hofmann,
2011) and therefore are not the focus of this review. The
frequently used deposition models for the development of
software programs are single path and multiple path models.
Single path models are based on empirical and semi-empirical
correlations. An important example for single path models is
the development of a whole lung model belongs to International
Commission on Radiological Protection (ICRP) for deposition
and retention of inhaled radioactive particles (ICRP, 1994).
Calculation is based on a five compartment model, comprising
the anterior nose; the posterior nasal passages together with
larynx and pharynx; the bronchial regions; the bronchioles and
the alveolar region. An alternate model has been developed by
the National Council on Radiation Protection andMeasurements
(NCRP) (National Council on Radiation Protection, 1997).
One of the main differences between these models is that
the NCRP model divides the lungs down to several airway
generations and, thereby, includes considerably more detail of
the lung geometry than the ICRP model. The ICRP model
classifies the empirical correlations into two subcategories: those
governed by the aerodynamic diameter (for larger aerosols that
are impaction- or interception-driven) and those governed by
the thermodynamic diameter (for smaller aerosols driven by
thermodynamic diffusion). Both models take also into account
the amount of clearance through different regions of the lungs.
Improvements of the ICRP model regarding shape factor, size
distribution and correlation of lung parameters to height have
been included in a more recently published model (Guha et al.,
2014). In this model a correlation was developed between height
and age, allowing calculation of lung deposition in all subjects as
a function of height rather than age. Flow rate and tidal volume
were functions of height and activity (sitting, sleeping, and light
exercise). The ICRP model is considered as a standard model
for routine inhalation dosimetry assessments (ICRP, 1994) and
has been also integrated in software programs for calculating
the deposition rate of pharmaceutical aerosols. As input data the
ICRP model uses physiological parameters and environmental
factors. Physiological parameters, which can be also varied by the
user are age, tidal volume, airflow, and activity, also considering
the both nose- and mouth-breathing. The environmental factors
are aerosol size and shape. The ICRP software uses 78 m2 as lung
surface area (Guha et al., 2014).
Multi-path models have been developed to provide a more
realistic lung-modeling than the single-path approach. In
multi-path modeling, the lung asymmetry branching pattern and
path variation have been taken into account. This results in more
realistic determination of average deposition fractions. However,
the validation of such models with in vivo data is only possible
for total or regional deposition, but not at airway generation
level. An example for such models is the Multiple Path Particle
Dosimetry model (MPPD) (Asgharian et al., 2001; Price et al.,
2002). The parameters used by MPPD to calculate deposition
comprise four areas: the type of airwaymorphometry, the particle
properties, the exposure, and the possibility to evaluate the
deposition or the deposition and clearance of the particles.
Regarding the airway morphometry, there is the possibility to
select between the human and the rat species. More in the
specific, five different morphometry are available for the human
and only one for the rat.
Morphometry includes the number of airways, individual
airway dimensions, spatial structure of branching network and
ventilatory conditions. Considering the selected morphometry
and resulting specific air flow patterns (laminar or turbulent), it
is possible to choose between a uniform and a non-uniform air
flow velocity. Other morphometric parameters that can be varied
are the FRC (Functional Residual Capacity) and the URT (Upper
Respiratory Tract) volume. The physico-chemical characteristics
of the particles, which are used to determine their lung deposition
in MPPD, are the density, the particle mean diameter (either as
Count Mean Diameter (CMD), Mass Mean Diameter (MMD)
or MMAD) and the Geometric Standard Deviation (GSD).
Inhalability of nanoparticles can also be taken into account. The
type of exposure can be selected between constant and variable,
thus to simulate, respectively, the deposition from breathing
at a fixed tidal volume and breathing frequency, or from an
environmental exposure which can change over time. For the
simulation of the deposition under constant conditions, the
parameters that can be defined are: the body orientation in
the space, the aerosol concentration, the breathing frequency,
the tidal volume, the inspiratory and pause fractions and the
breathing scenario. For the variable exposure, the parameters to
be defined are: the time of exposure, the particle concentration,
the breathing frequency, the tidal volume, the inspiratory and
pause fractions, the breathing scenario and the time indication
(activity or hourly pattern). Finally, the user can select to
investigate only the deposition or to account also for clearance
of the particles. The latter case can be selected only in the case
of constant exposure. The parameters that have to be defined
comprise the mucus velocity at the trachea, the type of clearance
and settings for the exposure time. The greater flexibility and
most importantly the possibility to include breath holding time
makes the MPPD model useful for calculation pharmaceutical
aerosol deposition (e.g., Ahmed et al., 2012; Longest and
Holbrook, 2012;Wu et al., 2013). A specifically adapted version of
the MPPD model can also take hygroscopic growth, coagulation
and evaporation of semivolatiles into account (Kane et al., 2010).
Not only deposition, which depends on particle properties and
physiological parameters, but also other parameters of the lung
linked to absorption, namely internal lung surface (absorption
area) and the amount of fluid that covers the pulmonary surface,
are difficult to determine in vivo.
ABSORPTION AREA
In opposite to respiratory tract, the surface area of the
gastrointestinal tract has been determined many years ago and
have been corrected only recently by Helander and Fandriks
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(Helander and Fandriks, 2014). The group determined the
surface area of stomach, small and large intestine as 35 m2, with
a contribution of 2 m2 for the large intestine (Helander and
Fandriks, 2014), while the older data indicated areas of small
and larger intestine of 120 m2 and 4 m2, respectively (Niazi,
2007). These differences were caused by the different evaluation
methods. Older techniques distended the intestine of cadavers
with a pressure of 40 cm and fixed the tissue with an aqueous
solution of 4% formalin (Wilson, 1967). Samples of this tissue
were taken at certain intervals, embedded in paraffin and sections
cut and stained for stereological histology. Values obtained by
the stereological calculations were corrected for shrinkage of
the tissue due to fixation. The new studies used radiological
investigations, supplemented with studies of the microscopical
structure for their analysis.Most importantly, parameters had not
been determined in complete relaxation of the gastrointestinal
tract (cadavers or surgery), but in conscious individuals.
Similar technological improvements are not available for
measurements of the lung surface and stereological histology is
still the preferred method to determine the internal surface of
the lung. The technology has been developed in the 1960s and
included the following steps: lungs were fixed by formalin steam
fixation and quantitative histological analysis of sagittal slices of 1
cm thickness was performed. The volume of fresh and fixed lungs
was corrected for tissue shrinkage during fixation. The surface
area estimation was based on the model that similar bodies of a
given volume and surface area were enclosed at random in a unit
volume. This volume was transversed by a number of lines with
a known total length. The total length of interior lines and the
number of intercepts were included in the calculation (Dunnill,
1962). Steam vapor fixation with formalin turned out to be better
than intrabronchial instillation of 4% formalin solution, because
no distortion of the alveolar spaces occurred (Hasleton, 1972).
Under these conditions lung surface was determined as 24–69
m2. Thurlbeck indicated the internal surface of the lung as 63
m2 when using inflation of the lungs with 10% formalin vapor
and maintenance of transbronchial pressure at 25 cm for 18
h (Thurlbeck, 1967). By combination of stereological histology
with electron microscopy, Weibel indicated the internal lung
surface area to be about 130 m2 (Weibel, 2009) in one study
and 150–180 m2 in another (Weibel, 1980). This data led to the
popular comparison of the lung area to a tennis court. However,
other estimations give 1 m2/kg body weight as realistic value for
lung surface of mammals (Lenfant, 2000). This estimation could
also be valid for humans because a lung surface of 70 m2 has
been reported (Bocci, 2011). This area corresponds to the size
of a single badminton court or one half of a tennis court. To
complicate the situation further, the inner lung surface markedly
depends on the inhalation state. Respiratory changes in lung
surface were studied by von Hayek, who reported a volume of
35 m2 at deep expiration and 100 m2 at deep inspiration (von
Hayek, 1960). The strong dependence of the lung area from the
respiration state could be an explanation for the variable volumes
indicated in the literature. Data from freshly excised lungs using
20 cm H2O for full inflation of the lung show that the choice of
25 cm H2O transbronchial pressure for the determination of the
internal lung surface should be sufficient to allow the evaluation
of the entire lung (Choong et al., 2007). Lower pressures of 14.0–
20.6 cm H2O were used to study ventilation mechanics studied
in the explanted lungs. Pressures below 30 cm H2O are also
recommended in mechanical ventilation of patients in order not
to damage the respiratory system (Malhotra, 2007).
DISTRIBUTION VOLUME AND PROTEIN
CONTENT
Distribution volume and binding to proteins are relevant
parameter for the availability of drugs (Smith et al., 2010). The
volume of fluid in the different parts of the gastrointestinal
tract have been determined in post-mortem studies, using
isotopes and, more recently, magnetic resonance imaging (MRI),
which possess sufficient resolution to determine these values
(Sutton, 2009). Catheters measurements indicated 120–350 ml
of residual water in the small intestine (Dillard et al., 1965)
while MRI studies reported 10–250 ml (mean 90 ml) in one
study and 25–350ml (mean 165ml) in another (Hoad et al.,
2007). Variations in these values appear to be due to the different
study design and time points of the measurements and not to
different determination techniques. Particularly the time between
water intake and measurement was important because water is
readily absorbed from the small intestine and measurements at
later time points result in smaller measured volumes. In regions
with less pronounced absorption like the colon, variations in
the fluid content between the studies were much smaller (22–30
ml) (Wang and Urban, 2014). Gastrointestinal fluid consists of
secretions from the large gastrointestinal glands (pancreas, liver),
submucosal glands (Brunner’s glands) and intraepithelial mucus-
producing cells. There are changes in pH and ion concentrations
along the gastrointestinal tract, but the average total protein
content in the fasted state was relatively constant at 1.2 mg/ml
with variations between 0.8 and 2.4mg/ml (Ulleberg et al., 2011).
Gastric juice contains mainly pepsin (0.8–1 mg/ml) and 1.5
mg/ml mucin (Vertzoni et al., 2005). Compared to plasma total
protein (60–80mg/ml) or albumin levels (35–50 mg/ml) in blood
(Busher, 1990), the concentrations in gastrointestinal fluids can
be considered as low and suggest only low drug binding.
Determination of the lining fluid in the lung (LLF), also
called epithelial lining fluid (ELF) or airway surface liquid
(ASL), is more complicated than for the gastrointestinal fluids
because lung volumes are much smaller. The total volume of
LLF can be estimated based on bronchoalveolar lavage (BAL) or
by extrapolation of the thicknesses of the fluid layer covering
the respiratory epithelia. BAL is a diagnostic technique that
uses instillation of sterile saline (0.9%) solution commonly into
the segmental bronchus of right middle lobe with the aim to
characterize cells but also to determine composition of the LLF
and measure drug levels. The procedure has been refined over
time; older protocols used the instillation of 3–7 l of fluid
with 500 ml aliquots while current protocols recommend 200–
240 ml (Klech and Pohl, 1989). This adaptation was needed
because concentrations of protein and drug levels are based on
the concentration of urea. Urea as non-polar small molecular
weight molecule crosses the alveolar epithelium and is expected
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to be present in the same concentration in the blood and
in the lung fluid. However, urea also leaks into the airspace
and in this way may reach higher levels than in the blood
with the consequence of overestimation of the LLF volume
(Baldwin et al., 1991). Volume and duration of the dwell time
are crucial parameters for the concentration of urea in BAL, and
dwell times <30 s are recommended (Tyvold et al., 2007). The
volume of the BAL is further relevant because upon instillation
of 300 ml saline 100 ml of BAL contain only 1 ml of LLF
(Rennard et al., 1986). Determinations of the LLF volume based
on the thickness of the fluid layer on top of the epithelia
require a technique that does not alter the native structure of
the LLF. Traditionally, transmission electron microscopy has
been used using fixation with glutaraldehyde and staining with
OsO4 in perfluorocarbon to preserve the mucus layer. To avoid
tissue shrinkage by the fixation, cryofixation instead of chemical
fixation has been developed (Kesimer et al., 2013). Cryofixation
determined the thickness of the periciliary layer of the bronchi
with 10–11 µm while older measurements using conventional
fixation indicated 7 µm (Tarran et al., 2005). Furthermore,
cryofixation allowed the visualization of the substructure of this
layer, while the fixation with glutaraldehyde and staining with
ruthenium red could not (Kesimer et al., 2013). Most published
data were obtained with conventional fixation technique. The
thickness of the lining fluid layer was reported as 5–10 µm
in the conducting airways and 0.01–0.08 µm in the alveoli
(Olsson et al., 2011). Other data report a 10–30 µm thick layer
in the trachea, 2–5 µm in the bronchi, and 0.1–0.2 µm in
the alveoli (Wauthoz and Amighi, 2015), 10 µm in the upper
airways, 3–5 µm in the alveolar ducts and 0.3 µm in the alveoli
(National Research Council, 1977) or 8.3–6.9 µm in bronchi
and 1.8 µm in bronchioles (Hoffmann et al., 2014). Patton
and Byron reported 8 µm for bronchi, 3 µm for terminal
bronchioles and 0.07 µm for alveoli (Patton and Byron, 2007).
The indication of an average thickness for bronchi does not
reflect the physiological condition of a highly variable and partly
discontinuous mucus layer. Focal increases of the layer of 20
times can occur and some small bronchi may completely lack
a mucus layer (Hiemstra, 2010) and could cause heterogenous
absorption of the drugs.
There is currently no optimal method to determine the
volume of the LLF. Calculation by the urea method poses the
problem of overestimation due to leakage of urea. Estimations
based on the thickness of the lining fluids needs to avoid fixation
artifacts and are complicated by the variable indications of the
entire lung surface area. Most existing data were obtained with
the measurement of urea in BAL. In the literature different
volumes of 12 ml (Schlesinger, 1992), 20–40 ml (Lenfant, 2000),
25 ml (Walters, 2002), 10–30 ml (Olsson et al., 2011) and
17–20ml (Bocci, 2011) have been indicated. Greater variations
of 15–70 ml were given by Bohr et al. (Bohr et al., 2014).
Based on the body weight-dependent data obtained in sheep
(0.37 ± 0.15 ml/kg), a 70 kg human would possess 26 ml of
LLF (Stephens et al., 1996). This study used the instillation of
the impermeant tracer 125I-albumin in perfused postnatal sheep
lungs and changes in the tracer concentration were measured.
Using low temperature scanning electron microscopy Fronius
et al. calculated the LLF volume in rat lungs based on the height
of the fluid layer (Fronius et al., 2012). Animal experiments may
offer a platform to establish new techniques for determination of
these data.
LLF has a heterogeneous composition that varies from the
larger to the smaller airways. Large airways possess periciliary
layer and gel mucus layer (Figure 1A). The periciliary layer
consists mainly of water with antibacterial factors, ions and
contains tethered mucins MUC1 and MUC4 and heparin
sulfate (Rubin and Henke, 2016). The ion content of the
layer is regulated by sodium uptake via the sodium channel
and chloride export transporters (calcium-activated chloride
channel and cystic fibrosis transmembrane ion conductance
regulator). The mucus gel layer consists of 97% water and 3%
solids, representing polymeric mucins MUC5AC and MUC5B
(Fahy and Dickey, 2010; Button et al., 2012). The network is
formed by entanglement and non-covalent calcium-dependent
crosslinking of adjacent polymers. The consistency of normal
mucus with 3% solids corresponding to the viscosity of egg
FIGURE 1 | Composition of the lung lining fluid of large airways
(bronchi, A) and alveolus (B). The blue arrow indicates exchange between
alveolus and blood vessel (BV). Alveolar type I cells (AT1) represent the
predominating cell type of the epithelial lining of the alveolus. Surfactant
production (small arrows) occurs in endoplasmic reticulum and Golgi
apparatus of the alveolar type II cells (AT2) and the surfactant layer self
assembles upon secretion from the cells. BC, bronchial epithelial cell; EC,
endothelial cell; M8, alveolar macrophage, erythrocyte (E).
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white; in pathologies, solids in the mucus can increase up
to 15%, which results in a consistency of the mucus similar
to rubber gum. The LLF of the alveolar region is composed
of a watery layer (hypophase) and surfactant (Fehrenbach,
2001). The hypophase contains surfactant proteins, complement
proteins and antioxidants (Kobzik, 2007) and provides the milieu
for alveolar macrophages that migrate on top of the alveolar
epithelial cells (Fehrenbach, 2001). The correct position of the
macrophages inside the hypophase was only realized when
perfusion fixation instead of immersion fixation of the lung
samples was used (Filippenko, 1978) and demonstrates that
improved analytic methods may help to obtain more relevant
physiological data. LLF consists of products of alveolar cell type
II (Figure 1B) and transudation of fluid from alveolar capillaries
(Hiemstra, 2010). Due to the variations in the employed BAL
protocols total protein levels were given as 5.3 mg/ml and 7
mg/ml to 9.0 mg/ml in healthy adults (Holter et al., 1986; Bocci,
2011; Olsson et al., 2011). Older protocols using larger BAL
volumes measured 1.3 mg/ml (Fick et al., 1984) consistent with
the theory that greater instilled volumes lead to overestimation of
the LLF volume and underestimation of protein concentrations.
The protein content of the LLF in the alveoli (5.35mg/ml) was
higher than in the lining fluid of bronchus (3.66 mg/ml) (Olsson
et al., 2011). According to the hypothesis by Baldwin et al. protein
levels in the ELF represent 6.5–8% of the plasma concentration,
which was quite close to the experimental values of 11.7mg/ml
and 7.9 mg/ml determined in their study (Baldwin et al., 1991).
Other studies report albumin levels in ELF of 3.0± 1.0mg/ml, 3.2
± 1.7 mg/ml, and 3.7± 0.3 mg/ml (Rennard et al., 1986; Chastre
et al., 1987; Lamer et al., 1993). These values indicate a low
drug binding of ELF. Blood and LLF are in constant exchange to
maintain composition of the hypophase because alveolar fluid is
replaced 20 times per day due to loss by respiration (700ml/day)
(Fronius et al., 2012).
EFFECTS OF SIMULATION PARAMETERS
ON DEPOSITION AND
PHARMACOKINETIC PROFILES
Several parameters affect the modeling of lung deposition,
including the selected lung morphology, the respiratory
parameters, determining air flow pattern through the lung
and the clearance velocity, particle properties such as size and
shape of particles and the deposition mechanisms. Mathematical
calculations for deposition commonly refer to spherical particles
and selected morphometric lung models for healthy, adult
subjects. The major limitation for the application of deposition
models is the intersubject variability of morphological and
physiological parameters, which affects the validation of
models with experimental data (Rosati et al., 2004; Hofmann,
2011). Moreover, linking the simulation data (deposition and
pharmacokinetics) to the used lung surface area and lining fluid
is problematic. In the MPPD software calculations are based
on 57.22 m2 for human alveolar surface and 0.297 m2 for rats
(EPA United States Environmental Protection Agency, 2004),
while another group indicated 102 m2 and 0.4 m2 as default lung
surface area of this software for humans and rats, respectively
(Chen and Chen, 2016). Differences in lung deposition are,
however, not only influenced by lung surface area and airflow
but also by fluid dynamics of the inhaled air. Comparing
different simulation programs Majid et al. noted prominent
variations in deposition; 100% variation was due to differences in
diffusion deposition and 300% of variations due to impactation
(Majid et al., 2012). In addition to that, the dose at the alveolar
epithelium is not only determined by deposition but also by
clearance. Hofmann and Asgharian (2003) used an asymmetric,
multipath model for computational assessment of mucociliary
clearance velocities in bronchial airways of the human and rat
lung (Hofmann and Asgharian, 2003). The experimental slow
bronchial clearance values of particles smaller than 6.7 µm
were explained by the delayed mucociliary clearance of particles
deposited in the most peripheral conductive airways, but could
not be fitted with the computational data. For acinar deposition
(deposition in airways that are partly or fully alveolated),
computational predictions were lower than the experimental
values. This might be caused by translocation of particles initially
deposited in the bronchioles to the acinar region because of the
slow bronchial clearance in bronchioles (Hofmann and Sturm,
2004). The interstitial/sequestration model considers the slow
clearance in bronchioles (Kuempel et al., 2006) and differs in
this respect from MPPD and ICRP software. The interstitial-
sequestration model has been developed as improvement of the
ICRP model for insoluble materials (Gregoratto et al., 2011).
According to this model 35% of the deposited material remains
sequestered in the interstitium.
Differences in surface area of the human lung have practical
consequences on the doses that are applied to animals in
order to create realistic exposure scenarios. For this calculation
the dose adaptation factor (DAF) is calculated using the ratio
of minute ventilation (VE; animal/human) multiplied by the
ratio of deposition fraction (DF; animal/human) and by the
normalization factor (NF; area human lung/ area animal lung).
DAF =
(VE)A
(VE)H
×
DFA
DFH
×
NFH
NFA
For calculation of the NF various combinations of human and
rat surface areas have been used in the literature, e.g., 62.7 m2
for humans and 0.409 m2 for rats (Ji and Yu, 2012), 143 m2 for
humans and 0.48 m2 for rats, 62.7 m2 for humans and 0.55 m2
for rats (Yu, 1996) and 79 m2 for human lung and 0.29 m2 for
rat lungs (Jarabek et al., 2005). Due to the fact that lung area can
be more accurately determined in rats than in humans the values
used in the studies varied by a factor of 1.8, while maximum and
minimum human values for humans varied by a factor of 2.5.
The dose adaptation factor, however, also contains other
parameters and the effect of different lung areas used
for the normalization factor might be compensated or
amplified by changes in the ratios of minute ventilation
and deposition fraction. The U.S. Environmental Protection
Agency summarized studies on minute ventilation in rats;
data obtained by plethysmography in studies between 1960
and 1978 varied between 0.05 and 0.237 L/min (Arms and
Travis, 1988). Minute ventilation in humans ranged between
6.02 and 7.5 L/min. Less pronounced inter-study differences
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(0.14–0.39 L/min; studies 1964–1992) in rat minute ventilation
were observed in a report of the Defense Research Establishment
(Bide et al., 1997). Minute ventilation is usually calculated
based on body weight using recommended allometric equations.
Minute ventilation normalized to body weight varied relatively
little between different studies, 0.64–0.8 L/min/kg for rats and
0.09–0.13 L/min/kg for humans, indicating that these differences
might not have a great effect on the dose adaptation factor.
The ratio of the deposition fraction is influenced in a complex
manner as described above.
The link between lung lining fluid and results in
pharmacokinetic studies is complicated by the fact that
usually plasma levels are predicted. Lung tissue levels are
not easy to obtain in humans; the disadvantages of BAL
measurements have already been mentioned, lung biopsies are
not representative for the entire lung and represent only one
time point and lung microdialysis is a highly invasive technique
(Feuerstein and Zeitlinger, 2011). Lung microdialysis would be
the ideal technique because continuous measurements of lung
concentrations are possible. Since the probe for microdialysis
sampling of the interstitial fluid has to be inserted under
visual control during thoracotomy, only very few data have
been generated and drug levels are usually measured in blood
samples. Blood levels are usually very low, caused by multiphasic
absorption and downstream of the lung. Inhaled drugs are
absorbed by branches of the pulmonary artery, which runs in
parallel to the bronchial tree, and then follow the blood stream
through the left atrium of the heart, the left ventricle, the aorta,
and the arteries and capillaries of the upper extremity to reach
the cubital vein, where blood samples are collected.
A variety of parameters determine drug plasma levels and the
influence of specific parameters to the results of the prediction is
difficult to discern. However, when looking only on absorption
a potential link might be apparent. The study by Gaohura
et al. predicted the ratio of drug concentrations in LLF to
plasma and the ratio of LLF: lung tissue concentrations using
a multicompartment lung model (Gaohua et al., 2015). In
their study the authors predicted these ratios for tuberculostatic
drugs based on 25 ml lining fluid and 140 m2 lung surface
area. Results were in reasonable agreement (within 2.5-fold) for
rifampicin, ethambutol, isoniazid, and erythromycin and too
low for itraconazole, pyrazinamide, and clarithromycin (13-fold,
16-fold, and ∼26-fold). When comparing simulated LLF and
peak plasma concentrations of rifampicin in vivo plasma levels
were at the maximum 2-fold higher and LLF concentrations
almost 8-times higher. Lowering the pH of the lining fluid
and inclusion of transporter activity in the model reduced the
degree of underestimation of the LLF:plasma ratio but the trend
remained and it might also be suggested that the great surface
area that was used in the predictions played a role. Under the
assumption that a greater lung surface enables better uptake of
the compounds and result in higher plasma levels the LLF:plasma
ratio would decrease. Another reason could be that the volume
of LLF in the model was too low and, as a consequence, the drug
concentration to high. Since the equations of the model were not
indicated and other parameters (published data, blood flow rate,
ventilation/perfusion, tissue volume, extrapolated permeability
etc.) also influence the simulation, such a conclusion, however,
remains highly speculative.
CONCLUSION
Variable data for lung surface and LLF in the literature illustrate
the problems in choosing the right preset values for simulation
of lung absorption. Reported variations in the LLF result in
differences of 7 times in the potential dissolution volume of the
drug. For the absorption area differences are in the same order of
magnitude (7.5 times). Improved and new techniques helped in a
better determination of physiological data and new technologies
may prove that the current textbook data are not correct. Data
derived from animals, where more invasive methods can be
applied, may be helpful to better include the dynamic changes of
lung parameters during oral inhalation of drugs. Several factors
influence deposition of particles and absorption of drugs and it
is, therefore, difficult to link the effect of individual parameters
to the result of the simulation. In general, a greater surface area
appears more realistic when simulating therapeutic inhalation,
while smaller surface areas are realistic for environmental
exposure. Deep inhalation causes increase of lung surface area
but is also accompanied by higher airflow and both parameters
will influence particle deposition in a complex way. Furthermore,
true alveolar surface available for gas is 20–50% smaller than the
epithelial surface depending on the level of air space inflation. At
full inflation of 140 m2, for instance, the “true” alveolar surface is
only 70–100 m2 (Gehr et al., 1978). It appears likely that different
surface area values are relevant for deposition and absorption
because the lung surface area gets smaller after the inhalation
maneuver has finished and this fact has to be taken into account
in calculations of drug absorption. Intersubject variability of
lung deposition is a major limitation for general using of such
models for in silico predictions. Implementation of the dynamic
changes of lung parameters in in silico models is a challenging
and complicated task.
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